PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2016; 05(03): 085-086
DOI: 10.4103/2278-330X.187552
Editorial Commentary

Breast cancer: Indian experience, data, and evidence

Sudeep Gupta
Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints


Publikationsverlauf

Artikel online veröffentlicht:
28. Dezember 2020

© 2016. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ghoncheh M, Momenimovahed Z, Salehiniya H. Epidemiology, incidence and mortality of breast cancer in Asia. Asian Pac J Cancer Prev 2016;17:47-52.
  • 2 Badwe RA, Gupta S. Breast cancer: An Indian perspective. Natl Med J India 2011;24:193-7.
  • 3 Ghosh J, Gupta S, Desai S, Shet T, Radhakrishnan S, Suryavanshi P, et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J Cancer 2011;48:391-6.
  • 4 Nagrani R, Mhatre S, Boffetta P, Rajaraman P, Badwe R, Gupta S, et al. Understanding rural-urban differences in risk factors for breast cancer in an Indian population. Cancer Causes Control 2016;27:199-208.
  • 5 Mittra I, Mishra GA, Singh S, Aranke S, Notani P, Badwe R, et al. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: Methodology and interim results after three rounds of screening. Int J Cancer 2010;126:976-84.
  • 6 Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: An open-label randomised controlled trial. Lancet Oncol 2015;16:1380-8.
  • 7 Parmar V, Hawaldar R, Nair NS, Shet T, Vanmali V, Desai S, et al. Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer. Breast 2013;22:1081-6.
  • 8 Badwe R, Hawaldar R, Parmar V, Nadkarni M, Shet T, Desai S, et al. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: A randomized controlled trial. J Clin Oncol 2011;29:2845-51.
  • 9 Ghosh J, Phillip DS, Ghosh J, Gupta S, Bajpai J, Gulia S, et al. Outcome with use of 12 weeks of adjuvant or neoadjuvant trastuzumab in a resource constrained setting. [Abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX, Philadelphia, (PA): AACR;  2016.  [Cancer Res 2016;76 4 Suppl: Abstract nr P4-14-07].
  • 10 Mannan AU, Singh J, Lakshmikeshava R, Thota N, Singh S, Sowmya TS, et al. Detection of high frequency of mutations in a breast and/or ovarian cancer cohort: Implications of embracing a multi-gene panel in molecular diassgnosis in India. J Hum Genet. 2016. doi: 10.1038/jhg.2016.4. [Epub ahead of print].